Table III.
COVID‐19 therapies and clinical outcomes.
| COVID‐19 therapies and clinical outcomes | n = 55 |
|---|---|
| Thrombotic event/anticoagulation | % (n/total) |
| Admission anticoagulation* | |
| Prophylactic low molecular weight heparin | 58% (26/45) |
| Therapeutic dose low molecular weight heparin | 13% (6/45) |
| Direct oral anticoagulants | 7% (3/45) |
| Thrombotic events | |
| Deep vein thrombosis | 5% (3/55) |
| Pulmonary embolism | 5% (3/55) |
| PICC‐associated superficial thrombophlebitis | 2% (1/55) |
| ICU/HDU level therapy | % (n/total) |
| CPAP | 35% (19/55) |
| Endotracheal intubation | 11% (6/55) |
| Renal replacement therapy | 2% (1/53) |
| Vasopressors | 10% (5/55) |
| Treatment escalation plans: | % (n/total) |
| Full escalation | 58·1% (32/55) |
| Escalation to NIV only | 29·1% (16/55) |
| Ward based therapies only | 12·7% (7/55) |
| DNACPR in place | 41·8% (23/55) |
| Outcomes | Days (range) |
| Median length of stay: | |
| In hospital | 13 (0–135) |
| In ICU | 7 (1–32) |
| Median duration of: | |
| CPAP | 4 (1–15) |
| % (n/total) | |
| Died in hospital | 35% (19/55) |
| Discharged from hospital | 64% (35/55) |
| Restarted haematological cancer‐directed therapy | 52% (14/27) |
FiO2, fraction of inspired oxygen; ICU, intensive care unit; HDU, high dependency unit; CPAP, continuous Positive Airway Pressure; DNACPR, do not attempt cardiopulmonary resuscitation; NIV, non‐invasive ventilation; PCR, polymerase chain reaction.
*
Data regarding baseline anticoagulation missing in 6/51 hospitalised patients.